p39 Control Protein
SDS-PAGE Results of p35 Control Protein
Western Blot of p35 Control Protein
Datasheet is currently unavailable. Try again or CONTACT US
Datasheet

p39 Control Protein

000-001-C17
100 µg
SDS-PAGE, WB
Borrelia burgdorferi
Have a Question? Ask a Specialist
$350.00 /Per Item
Availability: Ships next business day
Shipping info:

$50.00 to US & Canada for most products. Final costs are calculated at checkout.

Description

Background

The p39 protein, or Basic membrane protein A, is one of the immunogenic cell membrane components of Borrelia burgdorferi, the spirochete carried by Ixodes ticks. The spirochete migrates from the tick midgut during feeding to its salivary glands and are thus transmitted to the mammal host. This transition may be facilitated by changes in expression of some B. burgdorferi genes. It is believed that expression of the various proteins associated with the spirochete may be regulated by the changes in tick life cycle, changes in conditions during tick feeding (such as temperature, pH, and nutrients) and/or in coordination with the course of infection of the mammal host. BmpA is expressed during the invasion of the spirochete and in the evolution of the arthritis of Lyme disease in mammals. It belongs to the BMP lipoprotein family. The major products of the B. burgdorferi basic membrane protein (bmp) A/B operon that are induced in murine and human joints possess inflammatory properties. Non-lipidated and lipidated versions of BmpA have been shown to induce the pro-inflammatory cytokine TNF-α and IL-1ß in human synovial cells. The induction of cytokine responses in synovial cells via activation of the NF-kappaB and p38 MAP kinase pathways could potentially contribute to the genesis of Lyme arthritis. The BmpA outer-surface protein is an important antigen for serodiagnosis of human infection. B. burgdorferi adheres to host extracellular matrix components, including laminin, but may not bind mammalian type I or type IV collagens or fibronectin. Lyme disease proteins are ideal for researchers interested in immunology, neurology, rheumatology, coinfections, autoimmune, and neurodegenerative diseases.

Application Note

p39 is suitable as a control in immunological assays. Specific conditions for reactivity should be optimized by the end user. Expect a band at 77.8 kDa for p39-MBP, (35.4 kDa for p39 and 42.4 kDa for MBP) in size corresponding to p39 by Western blotting in the appropriate cell lysate or extract. p39 protein was tested in SDS-page and western blot.

Purity/Specificity

p39 is a fusion protein with an MBP tag and was expressed in E. coli. Analysis by SDS-PAGE resulted in a pattern consistent with purified p39 and was estimated to be greater than 90% pure.

p39 Control Protein - 000-001-C17
Basic membrane protein A, Borrelia burgdorferi bmpA, immunodominant antigen P39, membrane lipoprotein BmpA, control protein
bmpA, BB_0383
SDS-PAGE, WB
Borrelia burgdorferi
E. coli
Protein
Recombinant Protein
Liquid (sterile filtered)
0.994mg/mL by BCA assay
0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2
0.01% (w/v) Sodium Azide
None
Dry Ice
Store vial at -20 °C prior to opening. Aliquot contents and freeze at -20 °C or below for extended storage. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. Dilute only prior to immediate use.
Expiration date is six (6) months from date of opening.

Invalid lot number

If you need help finding your CofA, contact us

This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.

Related products to: p39 Control Protein